

# A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

<b>Submission date</b> 12/10/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 12/10/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/07/2018	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Cornel Pater

**Contact details**  
Hans-Boeckler Allee 20  
Hannover  
Germany  
30173  
+49 (0)511 857 2074  
[cornel.pater@solway.com](mailto:cornel.pater@solway.com)

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

S171.3.012

## **Study information**

### **Scientific Title**

A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

### **Acronym**

ASTRID (Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril and type 2 Diabetics)

### **Study objectives**

Not provided at time of registration

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

GP practice

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Essential Hypertension grade I and II

**Interventions**

Single, double- and triple- combination antihypertensive therapy, active controlled (monotherapy [eprosartan versus ramipril] followed by addition of hydrochlorothiazide as second agent and moxonidine as a third agent).

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/2004

**Completion date**

01/01/2006

**Eligibility****Key inclusion criteria**

Investigative centers from eight European countries and Canada (primary and secondary care) targeting patients with grade I - II hypertension and associated diabetes mellitus type 2. Goal blood pressure (BP) targeted: below 130/80 mmHg.

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2004

**Date of final enrolment**

01/01/2006

# Locations

## Countries of recruitment

Germany

United Kingdom

## Study participating centre

**Hans-Boeckler Allee 20**

Hannover

Germany

30173

# Sponsor information

## Organisation

Solvay Pharmaceuticals (Germany)

## Sponsor details

Hans-Boeckler Allee 20

Hannover

Germany

30173

## Sponsor type

Industry

## ROR

<https://ror.org/01xscrc43>

# Funder(s)

## Funder type

Industry

## Funder Name

GPS Solvay Pharmaceuticals

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	Protocol	01/10/2004		Yes	No